The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines
Open accessAbstract
mRNA vaccines have the potential to tackle many unmet medical needs that are unable to be addressed with conventional vaccine technologies. A potent and well-tolerated delivery technology is integral to fully realizing the potential of mRNA vaccines. Pre-clinical and clinical studies have demonstrated that mRNA delivered intramuscularly (IM) with first-generation lipid nanoparticles (LNPs) generates robust immune responses. Despite progress made over the past several years, there remains significant opportunity for improvement, as the most advanced LNPs were designed for intravenous (IV) delivery of siRNA to the liver. Here, we screened a panel of proprietary biodegradable ionizable lipids for both expression and immunogenicity in a rodent model when administered IM. A subset of compounds was selected and further evaluated for tolerability, immunogenicity, and expression in rodents and non-human primates (NHPs). A lead formulation was identified that yielded a robust immune response with improved tolerability. More importantly for vaccines, increased innate immune stimulation driven by LNPs does not equate to increased immunogenicity, illustrating that mRNA vaccine tolerability can be improved without affecting potency.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“which are known to have significantly higher delivery efficiency in hepatocytes after intravenous (i.v.) injection31 or in muscle cells after intramuscular (i.m.) injection.32”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [32]
In the citing paper
“Based on these observations, Moderna has developed an ionizable lipid (namely Lipid H, SM-102), whose tail adopts larger branches which in turn increases potency, and whose introduced ester bonds increase biodegradability (Fig. 7).290,291”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [291]
In the citing paper
“All three major players in the mRNA vaccine field have previously optimized so-called lipid nanoparticles (LNPs), constructs that typically consist of an ionizable lipid and one or more helper lipids to improve LNP stability and promote endosomal escape upon cellular uptake [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“For Moderna's LNP formulation, Hassett et al. reported that the SM-102 lipid was selected based on its improved tolerability profile in non-human primates, as evidenced by a reduced local reactogenicity (e.g., edema and erythema) and lowest induction of systemic cytokine responses (e.g., IL-6) [13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“the usage of the SM-102 lipid in Moderna's mRNA-1273 vaccine was found to outperform Onpattro's MC3 LNPs for the intramuscular (i.m.) delivery of mRNA in rodents and non-human primates, given its improved tolerability and higher endosomal escape efficiency [12,13]”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [13]
In the citing paper
“Endosomal escape can be increased by optimizing the pKa values of ionizable lipids66,76–78,88,100,140.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“To improve the biocompatibility of lipid nanoparticles, biodegradable lipids can be applied76–78,108,179.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
In the citing paper
“Moreover, the delivery efficacy of mRNA could be improved, for example, by rational design of lipids through modulation of head groups and hydrophobic tails to increase cellular uptake and endosomal escape of lipid nanoparticle–mRNA formulations64,66,76–78,88,97,100,114,140,141.”
From Lipid nanoparticles for mRNA delivery (2021) · cites this paper as [78]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Karikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Heterologous Protection Against Influenza by Injection of DNA Encoding a Viral Protein
Ulmer, J. B., Donnelly, J., Parker, S. E., Rhodes, G. H., Felgner, P. L., Dwarki, V., Gromkowski, S. H., Deck, R. R., DeWitt, C. M., Friedman, A., et al. (1993) · Science · doi:10.1126/science.8456302 · Cited by 2,318
Lanciotti, R. S., Kosoy, O. L., Laven, J. J., Velez, J. O., Lambert, A. J., Johnson, A. J., Stanfield, S. M., & Duffy, M. R. (2008) · Emerging infectious diseases · doi:10.3201/eid1408.080287 · Cited by 2,173
Rational design of cationic lipids for siRNA delivery
Semple, S. C., Akinc, A., Chen, J., Sandhu, A. P., Mui, B. L., Cho, C. K., Sah, D. W. Y., Stebbing, D., Crosley, E. J., Yaworski, E., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1602 · Cited by 1,822 · cited 1×
“8.(11,13,23) However, the best lipids with respect to protein expression after IV administration generally had lower pKas than the best lipids for protein expression after IM administration.”
Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo
Jayaraman, M., Ansell, S. M., Mui, B. L., Tam, Y. K., Chen, J., Du, X., Butler, D., Eltepu, L., Matsuda, S., Narayanannair, J. K., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203263 · Cited by 1,267
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208760 · Cited by 971
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. F. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 965
Modified mRNA vaccines protect against zika virus infection
Richner, J. M., Himansu, S., Dowd, K. A., Butler, S. L., Salazar, V., Fox, J. M., Julander, J. G., Tang, W. W., Shresta, S., Pierson, T. C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.02.017 · Cited by 909
Self-citationZika virus protection by a single low-dose nucleoside-modified mRNA vaccination
Pardi, N., Hogan, M. J., Pelc, R. S., Muramatsu, H., Andersen, H., DeMaso, C. R., Dowd, K. A., Sutherland, L. L., Scearce, R. M., Parks, R., et al. (2017) · Nature · doi:10.1038/nature21428 · Cited by 884
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 918
Formulation screening for local delivery of mRNA and photosensitizer to treat superficial tumor
Huang, L., Tang, S., Guo, J., Tu, Y., Li, S., Yang, T., Zhao, D. B., & Wang, C. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107525 · Cited by 2
Zong, Y., Wang, Y., Lin, Y., Li, Q., Li, M., Ren, H., Wang, X., Ma, Q., Yu, X., Hu, R., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.01.002 · Cited by 3
Empty lipid nanoparticles (eLNPs) with adjuvant activity induce potent immune responses
Qiu, D., Yan, S., Chen, R., Wu, S., Nie, M., Yang, M., Liu, Y., Wu, Y. Y.-C., Xiong, H., Yuan, Q., et al. (2026) · British Journal of Pharmacology · doi:10.1111/bph.70340 · Cited by 2
Durability of DNA-LNP and mRNA-LNP vaccine-induced immunity against SARS-CoV-2 XBB.1.5
Tamming, L. A., Lansdell, C., Zhang, W., Duque, D., Bavananthasivam, J., Frahm, G. E., Pfeifle, A., Raman, S. N. T., Wu, J., Gravel, C., et al. (2026) · npj Vaccines · doi:10.1038/s41541-026-01382-3 · Cited by 2
Zhang, Y., Johansen, M. D., Ledger, S., Shipley, R., Zhao, G., Moles, E., Turville, S. G., Thordarson, P., Hansbro, P. M., Kavallaris, M., et al. (2026) · Drug Delivery and Translational Research · doi:10.1007/s13346-026-02076-y · Cited by 2
Burghardt, T., Thalmayr, S., Obeser, L., Pöhmerer, J., Yazdi, M., Höhn, M., Völkl, M., Sieber‐Schäfer, F., Zahler, S., Merkel, O. M., et al. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.5c19141 · Cited by 2
Recent advances in LNP-mRNA vaccines
Redenti, B. J., Zhong, Y., Yu, C., & Dong, Y. (2026) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2026.115675 · Cited by 3
Kunyk, D., Vasileva, O., Bespalov, M., Dzharullaeva, A. S., Mazunina, E., Chubarova, A., Seliverstov, M., Smirnykh, D., Shevyrev, D., Shtraus, S., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.70335 · Cited by 2
Pulmonary mRNA-LNP vaccines for rapid and durable protection against bacterial infection
Wei, A., Miao, Y., Yuan, Z., Li, G., Lei, D., Ma, Y., Guo, Z., Sun, Y. W., Ding, T., Tian, K., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-75413-x · Cited by 2
Guérin, M., Saorin, A., & Martinez‐Serra, A. (2026) · Health Nanotechnology · doi:10.1186/s44301-026-00036-6 · Cited by 2
Bafleh, W. S., Abdulsamad, H. M. R., Al-Qaraghuli, S. M., Khatib, R. Y. E., Elbahrawi, R. T., Abdukadir, A. M., Alsawae, S. M., Dimassi, Z., Hamdan, H., & Kashir, J. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1198848 · Cited by 2
Park, H., Sut, T. N., Ferhan, A. R., Yoon, B. K., Zhdanov, V. P., Cho, N., & Jackman, J. A. (2023) · Langmuir · doi:10.1021/acs.langmuir.3c00777 · Cited by 2
mRNA Vaccines: Immunology and Present and Future Potential
Khan, O. F., Couture‐Senécal, J., Lau, Y. M. A., Oproescu, A.-M., Pang, J., Tilstra, G., & Walz, B. A. (2024) · Springer eBooks · doi:10.1007/978-3-031-62772-9_5 · Cited by 2
mRNA vaccine delivery strategies for cancer therapy
Zhang, H., Zhang, H., Xu, B., & Liu, H. (2024) · Chinese Science Bulletin (Chinese Version) · doi:10.1360/tb-2024-0670 · Cited by 2
Guo, Y., Sun, T., Li, M., Chen, Z., Liu, Y., Luo, X., Chen, Y., Li, Y., Kuai, L., Xue, Y., et al. (2025) · Pharmaceutical Research · doi:10.1007/s11095-024-03807-x · Cited by 2
A Novel Piggyback Strategy for mRNA Delivery Exploiting Adenovirus Entry Biology
Lee, M., Rice-Boucher, P. J., Collins, L. T., Wagner, E., Aulisa, L., Hughes, J. A., & Curiel, D. T. (2022) · Viruses · doi:10.3390/v14102169 · Cited by 2
Abbas, A. M., Ghanim, R. W., Rudden, S., Schultz, D., Jang, B., Shakked, A., Kim, H., Dahlman, J. E., & Abramson, A. (2026) · ACS Nano · doi:10.1021/acsnano.5c18549 · Cited by 2
Chase, L. S., Zaleski, M. H., Morrell, L. J., & Brenner, J. S. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123369 · Cited by 2
Kafle, S., Montoya, B., Tang, L., Tam, Y. K., Muramatsu, H., Pardi, N., & Sigal, L. J. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102279 · Cited by 2
Farzani, T. A., Espinoza, N., Manafi, M. M., Welch, S. R., Coleman-McCray, J. D., Aida-Ficken, V., Spengler, J. R., Bergeron, É., Spiropoulou, C. F., Borges, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.17.699915 · Cited by 2
Nonclinical safety and biodistribution evaluation of HC009 mRNA vaccine against COVID-19 in rat
Liu, J., Chen, X., Chen, C., Wu, J., Xie, F., Li, J., Han, H., Zhao, Y., & Yang, Y. (2025) · Toxicology · doi:10.1016/j.tox.2025.154107 · Cited by 1
Ryoko, S., Koide, H., Song, F., Yonezawa, S., Hashimoto, M., Toyota, H., Oku, N., & Asai, T. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151718 · Cited by 1
The mRNA vaccine contributors: Assessing their impact through a mainstream lens
Ho, M. H., Liu, J. S., Wang, W., & Chuang, T. C. (2025) · Technological Forecasting and Social Change · doi:10.1016/j.techfore.2025.124200 · Cited by 1
He, Y., Huang, C., Ma, R., Xu, Y., Zheng, Y., Yang, X., Zhang, Y., Chen, J., Yan, P., Ma, Y., et al. (2025) · Materials & Design · doi:10.1016/j.matdes.2025.114456 · Cited by 1
Lysozyme Amyloid for Synthetic RNA Delivery
Beluzo, B., Ismail, M., Chuikov, S., Keshamouni, V. G., & Kanapathipillai, M. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17091094 · Cited by 1
A safe and broad-spectrum SARS-CoV-2 mRNA vaccine with a new delivery system for in-situ expression
Yu, W., Chen, X., Chen, Q., Chen, P., Liu, N., Li, Y., Tan, X., Zhang, Q., Rao, Y., Guo, M. S., et al. (2025) · Virologica Sinica · doi:10.1016/j.virs.2025.09.001 · Cited by 1
Next‐Generation Bio‐Reducible Lipids Enable Enhanced Vaccine Efficacy in Malaria and Primate Models
Coen, R. D., Kasmi, S., Dumbre, S. G., Baekens, L., Seynaeve, E., den Hauwe, L. V., Cantini, N., Garantoudi, A., Madeira, F. B., Marrot, A., et al. (2025) · Advanced Functional Materials · doi:10.1002/adfm.202509838 · Cited by 1
Patent analysis of mRNA therapy using deep learning
Cai, Y., Zhang, X., Zhang, X., Ren, J., Wang, P., Cong, J., Li, X., Zuo, H., Wei, B., & Liu, K. (2025) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-025-04734-3 · Cited by 1
Iftekhar, K., Sajid, K., Rafiq, M., & Khan, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-34671-2.00022-0 · Cited by 1
Terminal end groups of poly(ethylene glycol) reduce antigenicity
Shiraishi, K. (2025) · Polymer Journal · doi:10.1038/s41428-025-01128-3 · Cited by 1
Effect of ionizable lipid head and tail group modification on mRNA delivery efficiency
Park, S., Lee, K., An, H.-J., Lin, E., Kim, S., Kim, H., Jeong, S., Roy, S., Kang, Y. W., Yang, J., et al. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.107981 · Cited by 1
Fairlamb, M. S., Kumru, O. S., Hickey, J. M., Elbaz, N. M., Bevernaegie, R., Straeten, A. V., Vandekerckhove, K., Ingham, D. J., Neuenswander, S. A., Douglas, J. T., et al. (2026) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2026.104199 · Cited by 1
Lipid nanoparticles formulation strategies
Das, U., Sarkar, A., Bachhar, A., Barman, S., Roy, D., & Mandal, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00002-1 · Cited by 1
Kong, W., Dong, Z., Wei, Y., Liu, W., Li, S., Yang, Y., Ding, N., Yang, J., & Qi, J. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202531454 · Cited by 1
LNP-mRNA vaccines: Revolutionizing preventive medicine
Bhowmik, S., Kundu, S., Ghosh, S., Chowdhury, A. A., & Acharya, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45006-8.00007-0 · Cited by 1
Shimizu, Y., Furukawa, R., Kikuchi, M., Sugai-Bannai, M., Hirano-Kodaira, M., Tozaki, T., & Leung, G. N. W. (2026) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-026-06556-5 · Cited by 1
Murphy, A. I., Vargas, C., & Pomerantz, J. H. (2026) · Bone Reports · doi:10.1016/j.bonr.2026.101921 · Cited by 1
Protein circuits as programmable biomaterials
Li, H., Sajbel, K. C., & Xia, S. (2026) · Cell Biomaterials · doi:10.1016/j.celbio.2026.100458 · Cited by 1
Efficacy and Safety of Messenger RNA Vaccines
Batisani, K., & Chisompola, D. (2026) · Health Science Reports · doi:10.1002/hsr2.72595 · Cited by 1
Bisaminoquinoline-bridged lipid for potent mRNA vaccine delivery and anti-tumor immunity
Feng, Y., Xin, S., Huang, L., Li, Y. L., Yan, M., Cong, K., He, C., Shen, H., Ma, Z., Wang, L., et al. (2026) · Chinese Chemical Letters · doi:10.1016/j.cclet.2026.113123 · Cited by 1
Jamous, Y. F. (2026) · Pandemics · doi:10.3390/pandemics1020008 · Cited by 1
Zhou, S., Wang, Z., Xu, Y., Meng, T., Barrett, S., & Zhu, G. (2026) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6c00671 · Cited by 1
Macromolecular Design Principles for Polymer‐Lipid Hybrid Nanoparticles in RNA Delivery
Shao, B., Chen, M., & Liu, S. (2026) · Macromolecular Rapid Communications · doi:10.1002/marc.70402 · Cited by 1
Non-invasive nanoparticle barcoding in nonhuman primates
Jang, B., Zenhausern, R., Lian, L., Gentry, K., Abbas, A. M., Rudden, S., Shin, Y.-J., Doan, J., Loughrey, D., Curran, E. H., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03262-6 · Cited by 1
Suwanpitak, K., Sangnim, T., Srikoon, P., Panpipat, C., Wongkongkaew, N., Sriamornsak, P., & Huanbutta, K. (2026) · OpenNano · doi:10.1016/j.onano.2026.100319 · Cited by 1
In vivo CAR T cells on the highway: a roadmap for the next decade
Barden, M., Harrer, D. C., & Abken, H. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2722287 · Cited by 1
Safety, Stability Concerns, and Regulatory Aspects of Nanocarriers for Brain Delivery
Jitendra, N. N., Alam, M. I., Mazahir, F., & Yadav, A. K. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_13 · Cited by 1
Next-Generation Nanoparticle-Enabled mRNA Vaccines in the Treatment of COVID-19
Kole, E. B., Jadhav, K., Singh, R., Verma, R. K., Chatterjee, A., & Naik, J. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2025053265 · Cited by 1
Bioinspired Extracellular Vesicles for Enhanced Delivery of siRNA to Tumors
Shi, S., Lu, M., & Huang, Y. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_19 · Cited by 1
RNA Therapeutics: Bridging Discovery and Clinical Implementation
Sioud, M. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4742-4_1 · Cited by 1
Epoh, A. J., Doyle, J. H., Bajrovic, I., & Croyle, M. A. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115715 · Cited by 1
Khawsang, C., Prompetchara, E., Saithong, S., Tharakhet, K., Kaewpang, P., Yostrerat, N., Wangsoontorn, P., Pitakpolrat, P., Buranapraditkun, S., Puttikhunt, C., et al. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119037 · Cited by 1
Han, R., Zhang, A., Jiang, Y., Yin, S., Wang, T., Gao, X., Deng, Y., Li, Y., & Tan, W. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116369 · Cited by 1
Ferrillo, T., Santoro, F., Cicco, P. D., Guida, M., Carotenuto, A., Brancaccio, D., Borrelli, F., Moore, T. L., & Quaglia, F. (2026) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2026.140735 · Cited by 1
Anwar, S., Chan, K. Y. T., Zia, A., Beck, S. L., Moriyama, H., Lim, K. R. Q., Shah, M. N. A., Haque, U. S., Maruyama, R., Witzigmann, D., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.010 · Cited by 1
Muscle contribution in lipid nanoparticle mediated mRNA vaccine delivery and efficacy
Repellin, M., Ugel, S., Sanctis, F. D., Coudert, L., Wang, T., Anselmi, C., Andretto, V., Scionti, I., Dimastromatteo, J., Sidi‐Boumedine, J., et al. (2026) · Journal of Controlled Release · doi:10.1016/j.jconrel.2026.115128 · Cited by 1
Gillman, L., Suleski, D., Graham, M. E., Ginn, S. L., & Hassan, M. M. (2026) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.6c00618 · Cited by 2
RNA Size and Structure Modulate the Apparent p K a of Ionizable Lipid Nanoparticles
Priss, A., Lytvynenko, O., Vaněk, V., Sedlák, F., Šašková, K. G., & Cígler, P. (2026) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6c00177 · Cited by 1
Artificial intelligence can support the chemical design of multiepitope vaccine nanocarriers
Garcia-Atutxa, I., & Villanueva‐Flores, F. (2026) · Discover Chemistry. · doi:10.1007/s44371-026-00929-6 · Cited by 1
Chen, Y., Monkovic, J., Mughal, H., Chen, B., Thadhani, E., McMullen, P., Self, A., Chen, Y., Hu, Y., Detmer, S., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03310-1 · Cited by 1
Fatballs foster fabulous follicles
Turley, J. L., & Lavelle, E. C. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.009 · Cited by 1
Кордюкова, Л. В., & Shanko, A. V. (2021) · Biochemistry (Moscow) · doi:10.31857/s0320972521070022 · Cited by 1
Aditi, K., Kumari, N., Singh, P., Kumari, A., Deen, S. Y., & Kumar, R. (2023) · Microsphere · doi:10.59118/vqar2242 · Cited by 1
Drug Delivery Systems: Lipid Nanoparticles Technology in Clinic
Andhari, S. S., Gupta, R., & Khandare, J. J. (2023) · Springer eBooks · doi:10.1007/978-981-99-1284-1_12 · Cited by 1
Could the Spike Protein Derived from mRNA Vaccines Negatively Impact Beneficial Bacteria in the Gut?
Rubio‐Casillas, A., Fabrowski, M., Brogna, C., Cowley, D., Redwan, E. M. M. M., & Uversky, V. N. (2024) · COVID · doi:10.3390/covid4090097 · Cited by 1
Lipid-based vaccines against viruses including COVID-19
Gholap, A. D., Khuspe, P. R., Faiyazuddin, M., Uddin, M. J., Bhowmik, D. D., Said, R. P., Sonawane, K. S., Parit, S., & Hatvate, N. T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22374-7.00019-0 · Cited by 1
Chen, Y., Lombaerde, E. D., Bugler-Lamb, A. R., Zhong, Z., Schuijs, M. J., Gomez, C. M. B., Baere, J. D., Gontsarik, M., Lauwers, H., Deswarte, K., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202506954 · Cited by 1
Nucleic Acid Delivery across Biological Barriers
Miyata, K. (2021) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.20-00219-2 · Cited by 1
Nucleic acid-based vaccines of COVID-19 and their delivery systems
Yang, H., Zhang, M., Weng, Y., Cao, Y., & Huang, Y. (2021) · Scientia Sinica Vitae · doi:10.1360/ssv-2021-0051 · Cited by 1
Advances in vaccination to combat pandemic outbreaks
Dasari, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85662-1.00002-1 · Cited by 1
Gill, K., Minall, L., & Nassif, A. R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-814357-5.00007-6 · Cited by 1
BIOTECHNOLOGICAL RESEARCH IN THE CREATION AND PRODUCTION OF ANTIRABIC VACCINES
Krasnopolsky, Y. М. (2021) · Biotechnologia Acta · doi:10.15407/biotech14.04.028 · Cited by 1
A Comprehensive Review of Vaccines against Covid-19
Minh, P. H., Linh, V. K., Hải, N. T., & Tùng, B. T. (2021) · VNU Journal of Science Medical and Pharmaceutical Sciences · doi:10.25073/2588-1132/vnumps.4365 · Cited by 1
Applications of Spray-Dried Vaccines
Arpagaus, C. (2023) · Springer eBooks · doi:10.1007/978-3-031-24323-3_6 · Cited by 2
Gene Delivery Using Nanocarriers
Vhora, I., & Khatri, N. (2021) · Wiley eBooks · doi:10.1002/9781119769897.ch9 · Cited by 1
Suzuki-Okutani, M., Okamura, S., Tanggis, Sasaki, H., Lee, S. P., Yoshida, A., Goto, S., Matsumoto, M., Yamawaki, M., Miyazaki, T., et al. (2025) · eLife · doi:10.7554/elife.97532.2 · Cited by 1
Agrawal, S., Stokes, A. L., & Nelson, C. E. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.07.31.667476 · Cited by 1
Jiang, Q., Su, K., Li, G., Luo, H., Wang, H., Luo, J., Zhong, Y.-N., Li, Q., Zhang, Z., Zhang, H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.11.13.688269 · Cited by 1
Chang, C.-C., Shi, L., Choi, S. H., Pennati, A., Valkanioti, V., Capitini, C. M., Mecozzi, S., & Galipeau, J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.15.692195 · Cited by 1
Classes, Modes of Action and Selection of New Modalities in Drug Discovery
Valeur, E. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160691-00277
COVID-19 Vaccines: Fabrication Techniques and Current Status
Kaur, L., Mahajan, A., Singh, G., Dhawan, R. K., Singh, L., & Kaur, A. (2021) · Coronaviruses · doi:10.2174/2666796702666210728150704
COVID-19: Vaccines on Their Marks
Jagtiani, E., & Vithlani, D. (2021) · The Bombay Technologist · doi:10.36664/bt/2021/v68i1/162888
Pharmacological Agents for COVID-19 Patients
Johnson, D. W., Searcy, R. J., & Whisenant, B. (2021) · Springer eBooks · doi:10.1007/978-3-030-85636-6_15
He, X. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.738957376.793579986
Delivery and Formulation Methods for Therapeutic Genome Editing
Blenke, E. O., & Krishnamurthy, V. R. (2022) · Wiley eBooks · doi:10.1002/9781119671404.ch18
Answering to social issues – Delivery of mRNA vaccines and therapeutics
Uchida, S. (2022) · Drug Delivery System · doi:10.2745/dds.37.25
Adverse effects of vaccinations and potential therapies against COVID-19
Wasiak, K., & Rieske, P. (2022) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2022.114392
Rapid vaccine development, only with the developed DDS technology
Takeda, M. (2021) · Drug Delivery System · doi:10.2745/dds.36.4
Lipid Nanoparticles to Harness the Therapeutic Potential of mRNA for Cancer Treatment
Guevara, M. L., Persano, F., & Persano, S. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_14
SARS-COV-2 and Other mRNA Vaccines
Jackson, N. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_6
Jackson, N. A. C. (2022) · RNA technologies · doi:10.1007/978-3-031-08415-7_2
ARN mensajero (mRNA), una molécula con potencial aplicación terapéutica y preventiva
Rosas, G., Bobes, R. J., Cervantes‐Torres, J. B., Sciutto, E., & Fragoso, G. (2022) · Inventio, la génesis de la cultura universitaria en Morelos · doi:10.30973/inventio/2022.18.44/8
Sellers, R. S., & Nelson, K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821047-5.00029-4
Sayed, M., Emam, S. E., El-Garhy, O. H., Sarhan, H. A., & Kamal, A. (2023) · Journal of advanced Biomedical and Pharmaceutical Sciences · doi:10.21608/jabps.2023.184283.1176 · Cited by 1
Azizah, D. N. (2023) · Sainsbertek Jurnal Ilmiah Sains & Teknologi · doi:10.33479/sb.v3i2.220
Thongbamrer, C., Yingyongnarongkul, B., Sakee, U., Nguitragool, W., & Radchatawedchakoon, W. (2023) · New Journal of Chemistry · doi:10.1039/d3nj02503a
The COVID-19 pandemic – lessons (un)learned – the aftermath
Rieske, P., & Pawliczak, R. (2023) · Alergologia Polska - Polish Journal of Allergology · doi:10.5114/pja.2023.131713
Silva, J. M. E., Guimarães, J. B., Jamra, S. R. A., Mirante, B. S., Capato, C. F., Jorge, D. M. D. M., & da Fonseca, B. A. L. (2023) · Vaccine X · doi:10.1016/j.jvacx.2023.100395
Narmada, B. S., Dutta, R., Paleja, B. S., & Channavazzala, M. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-sitc2023.1275
Metadata
- Authors
- Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., Mihai, C., Lynn, A., McFadyen, I., Moore, M. J., Senn, J. J., Stanton, M. G., Almarsson, Ö., Ciaramella, G., & Brito, L. A.
- Affiliations
- Moderna Therapeutics (United States) (US)
- Corresponding author
- Brito, Luis A.
- ORCID
- Venue
- Molecular Therapy — Nucleic Acids
- Publisher
- Elsevier BV
- Published
- 2019-04
- Volume
- 15
- Pages
- 1-11
- ISSN
- 2162-2531 (ISSN-L)
- PMC
- PMC6383180
- OpenAlex
- W2914060533
- Cited by
- 927
- References
- 35
- Citations by year
- 2026: 141 · 2025: 202 · 2024: 162 · 2023: 140 · 2022: 128 · 2021: 114 · 2020: 35 · 2019: 5
- FWCI
- 23.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecular Therapy — Nucleic Acids (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Moderna Therapeutics
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- lipid nanoparticles, mRNA vaccines, intramuscular administration, ionizable lipids, biodegradable lipids, immunogenicity, tolerability, innate immune activation, non-human primates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
